miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 11, 2026

Aduro Clean Technologies annonce le lancement d’une offre publique souscrite d’un montant de 15,64 millions de dollars et d’un placement privé concomitant pouvant atteindre 7,17 millions de dollars

View original at globenewswire.com
Aduro Clean Technologies annonce le lancement d’une offre publique souscrite d’un montant de 15,64 millions de dollars et d’un placement privé concomitant pouvant atteindre 7,17 millions de dollars LONDON, Ontario, 11 juin 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The USD/CAD exchange rate published by the Bank of Canada on June 9, 2026 was 1 USD = 1.3947 CAD.

    60% confidence
  • Aduro's Hydrochemolytic technology uses water as a key agent in a chemical platform operating at relatively low temperatures and costs, enabling the recycling of low-value feedstocks into 21st-century resources.

    60% confidence
  • Aduro intends to use the net proceeds of the offering to fund expenses related to the design, engineering, and construction of its first commercial-scale industrial demonstration plant (FOAK Plant), to continue its research and development activities, and for general corporate purposes and working capital.

    60% confidence
  • The LIFE offering is also expected to close on or about the public offering closing date, or at any other date determined by the Company, but no later than 45 days from the date of the press release. The LIFE offering may be completed in one or more tranches.

    60% confidence
  • Closing of the public offering is expected on or about June 11, 2026, subject to customary closing conditions including listing of offered shares on TSX and Nasdaq and receipt of required exchange approvals.

    60% confidence
  • Certain insiders of the Company may participate in the LIFE offering, and any such participation will constitute a 'related-party transaction' under Multilateral Instrument 61-101, but the Company expects to rely on exemptions from formal valuation and minority shareholder approval requirements because neither the fair market value of the LIFE shares subscribed by insiders nor the consideration paid will exceed 25% of the Company's market capitalization.

    60% confidence

Data points we hold from this source

Aduro Clean Technologies Inc. · gross proceeds life offering max7169810 USD
Aduro Clean Technologies Inc. · total gross proceeds max22805214 USD
Aduro Clean Technologies Inc. · stock price15.20 USD
Aduro Clean Technologies Inc. · stock price cad21.20 CAD
Aduro Clean Technologies Inc. · shares offered life max471698 shares
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Aduro Clean Technologies annonce le lancement d’une offre publique souscrite d’un montant de 15,64 millions de dollars et d’un placement privé concomitant pouvant atteindre 7,17 millions de dollars — Source | Via News | es.VIA.NEWS